We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival.
- Authors
Nassif, Elise F.; Mlecnik, Bernhard; Thibault, Constance; Auvray, Marie; Bruni, Daniela; Colau, Alexandre; Compérat, Eva; Bindea, Gabriela; Catteau, Aurélie; Fugon, Aurélie; Boquet, Isabelle; Martel, Marine; Camparo, Philippe; Colin, Pierre; Zakopoulou, Roubini; Bamias, Aristotelis; Bennamoun, Mostefa; Barthere, Xavier; D'acremont, Bruno; Lefevre, Marine
- Abstract
Simple Summary: The prognosis of localized muscle-invasive bladder cancer is poor and the prognostic and predictive biomarkers of the response to treatment are lacking. We retrospectively investigated the role of the Immunoscore in the neoadjuvant setting, where the Immunoscore is a standardized quantitative assay of lymphocytes in the tumor microenvironment. We found it allowed for the stratification of patient prognoses and the prediction of response to neoadjuvant chemotherapy. (1) Background—The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response to neoadjuvant chemotherapy and survival outcomes. (2) Methods—This retrospective study evaluated the IS in 117 patients treated using neoadjuvant chemotherapy for localized MIBC from six centers (France and Greece). Pre-treatment tumor samples were immunostained for CD3+ and CD8+ T cells and quantified to determine the IS. The results were associated with the response to neoadjuvant chemotherapy, time to recurrence (TTR), and OS. (3) Results—Low (IS-0), intermediate (IS-1–2), and high (IS-3–4) ISs were observed in 36.5, 43.7, and 19.8% of the cohort, respectively. IS was positively associated with a pathologic complete response (pCR; p-value = 0.0096). A high IS was found in 35.7% of patients with a pCR, whereas it was found in 11.3% of patients without a pCR. A low IS was observed in 48.4% of patients with no pCR and in 21.4% of patients with a pCR. Low-, intermediate-, and high-IS patients had five-year recurrence-free rates of 37.2%, 36.5%, and 72.6%, respectively. In the multivariable analysis, a high IS was associated with a prolonged TTR (high vs. low: p = 0.0134) and OS (high vs. low: p = 0.011). (4) Conclusions—This study showed the significant prognostic and predictive roles of IS regarding localized MIBC.
- Subjects
FRANCE; GREECE; BLADDER tumors; CANCER chemotherapy; CANCER patients; CANCER relapse; COMBINED modality therapy; MULTIVARIATE analysis; T cells; TUMOR markers; TREATMENT effectiveness; RETROSPECTIVE studies; DESCRIPTIVE statistics
- Publication
Cancers, 2021, Vol 13, Issue 3, p494
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13030494